Connect
MJA
MJA

Chronic fatigue syndrome: progress and possibilities

Carolina X Sandler and Andrew R Lloyd
Med J Aust 2020; 212 (9): . || doi: 10.5694/mja2.50553
Published online: 6 April 2020

Summary

  • Chronic fatigue syndrome (CFS) is a prevalent condition affecting about one in 100 patients attending primary care.
  • There is no diagnostic test, validated biomarker, clear pathophysiology or curative treatment.
  • The core symptom of fatigue affects both physical and cognitive activities, and features a prolonged post‐activity exacerbation triggered by tasks previously achieved without difficulty.
  • Although several different diagnostic criteria are proposed, for clinical purposes only three elements are required: recognition of the typical fatigue; history and physical examination to exclude other medical or psychiatric conditions which may explain the symptoms; and a restricted set of laboratory investigations.
  • Studies of the underlying pathophysiology clearly implicate a range of different acute infections as a trigger for onset in a significant minority of cases, but no other medical or psychological factor has been reproducibly implicated.
  • There have been numerous small case–control studies seeking to identify the biological basis of the condition. These studies have largely resolved what the condition is not: ongoing infection, immunological disorder, endocrine disorder, primary sleep disorder, or simply attributable to a psychiatric condition.
  • A growing body of evidence suggests CFS arises from functional (non‐structural) changes in the brain, but of uncertain character and location. Further functional neuroimaging studies are needed.
  • There is clear evidence for a genetic contribution to CFS from family and twin studies, suggesting that a large scale genome‐wide association study is warranted.
  • Despite the many unknowns in relation to CFS, there is significant room for improvement in provision of the diagnosis and supportive care. This may be facilitated via clinician education.

  • 1 UNSW Fatigue Clinic, UNSW, Sydney, NSW
  • 2 Queensland University of Technology, Brisbane, QLD
  • 3 Kirby Institute for Infection and Immunity in Society, UNSW, Sydney, NSW
  • 4 UNSW Medicine, Sydney, NSW


Correspondence: a.lloyd@unsw.edu.au

Acknowledgements: 

Andrew Lloyd is supported by a National Health and Medical Research Council Practitioner Fellowship (1041897). We are grateful for the review of the manuscript by Phillip Peterson MD.

Competing interests:

No relevant disclosures.

  • 1. Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006; 367: 346–355.
  • 2. Rowe PC, Underhill RA, Friedman KJ, et al. Myalgic encephalomyelitis / chronic fatigue syndrome diagnosis and management in young people: a primer. Front Pediatr 2017; 5: 121.
  • 3. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. Washington, DC: National Academies Press (US), 2015.
  • 4. Clayton EW. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA 2015; 313: 1101–1102.
  • 5. Keech A, Sandler CX, Vollmer‐Conna U, et al. Capturing the post‐exertional exacerbation of fatigue following physical and cognitive challenge in patients with chronic fatigue syndrome. J Psychosom Res 2015; 79: 537–549.
  • 6. Bennett BK, Goldstein D, Chen M, et al. Characterization of fatigue states in medicine and psychiatry by structured interview. Psychosom Med 2014; 76: 379–388.
  • 7. Nijs J, Aelbrecht S, Meeus M, et al. Tired of being inactive: a systematic literature review of physical activity, physiological exercise capacity and muscle strength in patients with chronic fatigue syndrome. Disabil Rehabil 2011; 33: 1493–1500.
  • 8. Michiels V, Cluydts R. Neuropsychological functioning in chronic fatigue syndrome: a review. Acta Psychiatr Scand 2001; 103: 84–93.
  • 9. Cvejic E, Birch RC, Vollmer‐Conna U. Cognitive dysfunction in chronic fatigue syndrome: a review of recent evidence. Curr Rheumatol Rep 2016; 18: 24.
  • 10. Lloyd AR. Chronic fatigue and chronic fatigue syndrome: shifting boundaries and attributions. Am J Med 1998; 105: 7S–10S.
  • 11. Royal Australasian College of Physicians Working Group. Chronic fatigue syndrome: clinical practice guidelines — 2002. Med J Aust 2002; 176 (9 Suppl): S17–S55. https://www.mja.com.au/journal/2002/176/9/chronic-fatigue-syndrome.
  • 12. Griffith JP, Zarrouf FA. A systematic review of chronic fatigue syndrome: don't assume it's depression. Prim Care Companion J Clin Psychiatry 2008; 10: 120–128.
  • 13. Hickie I, Davenport T, Wakefield D, et al. Post‐infective and chronic fatigue syndromes precipitated by viral and non‐viral pathogens: prospective cohort study. BMJ 2006; 333: 575.
  • 14. Petersen I, Thomas JM, Hamilton WT, White PD. Risk and predictors of fatigue after infectious mononucleosis in a large primary‐care cohort. QJM 2006; 99: 49–55.
  • 15. White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br J Psychiatry 1998; 173: 475–481.
  • 16. White PD, Thomas JM, Kangro HO, et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet 2001; 358: 1946–1954.
  • 17. Jackson ML, Bruck D. Sleep abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: a review. J Clin Sleep Med 2012; 8: 719–728.
  • 18. Mariman AN, Vogelaers DP, Tobback E, et al. Sleep in the chronic fatigue syndrome. Sleep Med Rev 2013; 17: 193–199.
  • 19. Jason LA, McManimen S, Sunnquist M, et al. Examining the Institute of Medicine's recommendations regarding chronic fatigue syndrome: clinical versus research criteria. J Neurol Psychol 2015; 2: 25.
  • 20. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953–959.
  • 21. Reeves WC, Lloyd A, Vernon SD, et al. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res 2003; 3: 25.
  • 22. Jason LA, Helgerson J, Torres‐Harding SR, et al. Variability in diagnostic criteria for chronic fatigue syndrome may result in substantial differences in patterns of symptoms and disability. Eval Health Prof 2003; 26: 3–22.
  • 23. Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic encephalomyelitis/chronic fatigue syndrome. J Chronic Fatigue Syndrome 2003; 11: 7–115.
  • 24. National Institute for Health and Clinical Excellence. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management of CFS/ME in adults and children. London: NICE, 2007. https://www.ncbi.nlm.nih.gov/books/NBK53577/ (viewed Nov 2019).
  • 25. Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 2011; 270: 327–338.
  • 26. Brown A, Molly B, Nicole P, et al. The development of a revised Canadian myalgic encephalomyelitis chronic fatigue syndrome case definition. Am J Biochem Biotechnol 2010; 6: 120–135.
  • 27. Sunnquist M, Jason LA, Nehrke P, Goudsmit EM. A comparison of case definitions for myalgic encephalomyelitis and chronic fatigue syndrome. J Chronic Dis Manag 2017; 2: 21.
  • 28. Johnston S, Brenu EW, Staines D, Marshall‐Gradisnik S. The prevalence of chronic fatigue syndrome/ myalgic encephalomyelitis: a meta‐analysis. Clin Epidemiol 2013; 5: 105–110.
  • 29. Johnston S, Brenu EW, Staines DR, Marshall‐Gradisnik S. The adoption of chronic fatigue syndrome/myalgic encephalomyelitis case definitions to assess prevalence: a systematic review. Ann Epidemiol 2013; 23: 371–376.
  • 30. Brurberg KG, Fonhus MS, Larun L, et al. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open 2014; 4: e003973.
  • 31. Haney E, Smith ME, McDonagh M, et al. Diagnostic methods for myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162: 834–840.
  • 32. Williams TE, Chalder T, Sharpe M, White PD. Heterogeneity in chronic fatigue syndrome ‐ empirically defined subgroups from the PACE trial. Psychol Med 2017; 47: 1454–1465.
  • 33. Wilson A, Hickie I, Hadzi‐Pavlovic D, et al. What is chronic fatigue syndrome? Heterogeneity within an international multicentre study. Aust N Z J Psychiatry 2001; 35: 520–527.
  • 34. Ross SD, Estok RP, Frame D, Stone LR, Ludensky V, Levine CB. Disability and chronic fatigue syndrome: a focus on function. Arch Intern Med 2004; 164 (10): 1098–107.
  • 35. Vercoulen JH, Hommes OR, Swanink CM, et al. The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol 1996; 53: 642–649.
  • 36. Wilson J, Morgan S, Magin PJ, van Driel ML. Fatigue–a rational approach to investigation. Aust Fam Physician 2014; 43: 457–461.
  • 37. Knight S, Harvey A, Lubitz L, et al. Paediatric chronic fatigue syndrome: complex presentations and protracted time to diagnosis. J Paediatr Child Health 2013; 49: 919–924.
  • 38. Stadje R, Dornieden K, Baum E, et al. The differential diagnosis of tiredness: a systematic review. BMC Fam Pract 2016; 17: 147.
  • 39. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. QJM 1997; 90: 223–233.
  • 40. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. Occup Med (Lond) 2005; 55: 20–31.
  • 41. Katz BZ, Collin SM, Murphy G, et al. The International Collaborative on Fatigue Following Infection (COFFI). Fatigue 2018; 6: 106–121.
  • 42. Crawley E. The epidemiology of chronic fatigue syndrome/myalgic encephalitis in children. Arch Dis Child 2014; 99: 171–174.
  • 43. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2: 187–193.
  • 44. Lombardi VC, Ruscetti FW, Das Gupta J, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009; 326: 585–589.
  • 45. Groom HC, Bishop KN. The tale of xenotropic murine leukemia virus‐related virus. J Gen Virol 2012; 93 (Pt 5): 915–924.
  • 46. Wessely S, Chalder T, Hirsch S, et al. Postinfectious fatigue: prospective cohort study in primary care. Lancet 1995; 345: 1333–1338.
  • 47. Hopper B, Cameron B, Li H, et al. The natural history of acute Q fever: a prospective Australian cohort. QJM 2016; 109: 661–668.
  • 48. Weinstein A, Klempner M. Treatment of patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 1424–1425.
  • 49. Cameron B, Bharadwaj M, Burrows J, et al. Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load. J Infect Dis 2006; 193: 664–671.
  • 50. Vollmer‐Conna U, Lloyd A, Hickie I, Wakefield D. Chronic fatigue syndrome: an immunological perspective. Aust N Z J Psychiatry 1998; 32: 523–527.
  • 51. Cameron B, Hirschberg DL, Rosenberg‐Hassan Y, et al. Serum cytokine levels in postinfective fatigue syndrome. Clin Infect Dis 2010; 50: 278–279.
  • 52. Vollmer‐Conna U, Cameron B, Hadzi‐Pavlovic D, et al. Postinfective fatigue syndrome is not associated with altered cytokine production. Clinical Infectious Diseases 2007; 45 (6): 732–5.
  • 53. Sabath DE, Barcy S, Koelle DM, Zeh J, Ashton S, Buchwald D. Cellular immunity in monozygotic twins discordant for chronic fatigue syndrome. J Infect Dis 2002; 185 (6): 828–32.
  • 54. Lyall M, Peakman M, Wessely S. A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res 2003; 55: 79–90.
  • 55. Blundell S, Ray KK, Buckland M, White PD. Chronic fatigue syndrome and circulating cytokines: a systematic review. Brain Behav Immun 2015; 50: 186–195.
  • 56. Teodoro T, Edwards MJ, Isaacs JD. A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: systematic review. J Neurol Neurosurg Psychiatry 2018; 89: 1308–1319.
  • 57. Harrison NA, Brydon L, Walker C, et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry 2009; 66: 415–422.
  • 58. Kraynak TE, Marsland AL, Wager TD, Gianaros PJ. Functional neuroanatomy of peripheral inflammatory physiology: a meta‐analysis of human neuroimaging studies. Neurosci Biobehav Rev 2018; 94: 76–92.
  • 59. Morris G, Berk M, Puri BK. A comparison of neuroimaging abnormalities in multiple sclerosis, major depression and chronic fatigue syndrome (myalgic encephalomyelitis): is there a common cause? Mol Neurobiol 2018; 55: 3592–3609.
  • 60. VanElzakker MB, Brumfield SA, Lara Mejia PS. Neuroinflammation and cytokines in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a critical review of research methods. Front Neurol 2018; 9: 1033.
  • 61. Lange G, Wang S, DeLuca J, Natelson BH. Neuroimaging in chronic fatigue syndrome. Am J Med 1998; 105: 50S–53S.
  • 62. Tanaka M, Ishii A, Watanabe Y. Neural mechanisms underlying chronic fatigue. Rev Neurosci 2013; 24: 617–628.
  • 63. Walitt B, Ceko M, Gracely JL, Gracely RH. Neuroimaging of central sensitivity syndromes: key insights from the scientific literature. Curr Rheumatol Rev 2016; 12: 55–87.
  • 64. Meeus M, Nijs J, Vanderheiden T, et al. The effect of relaxation therapy on autonomic functioning, symptoms and daily functioning, in patients with chronic fatigue syndrome or fibromyalgia: a systematic review. Clin Rehabil 2015; 29: 221–233.
  • 65. Van Cauwenbergh D, Nijs J, Kos D, et al. Malfunctioning of the autonomic nervous system in patients with chronic fatigue syndrome: a systematic literature review. Eur J Clin Invest 2014; 44: 516–526.
  • 66. Martinez‐Martinez LA, Mora T, Vargas A, et al. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case‐control studies. J Clin Rheumatol 2014; 20: 146–150.
  • 67. Smith ME, Haney E, McDonagh M, et al. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162: 841–850.
  • 68. Sullivan PF, Evengard B, Jacks A, Pedersen NL. Twin analyses of chronic fatigue in a Swedish national sample. Psychol Med 2005; 35: 1327–1336.
  • 69. Kato K, Sullivan PF, Evengard B, Pedersen NL. A population‐based twin study of functional somatic syndromes. Psychol Med 2009; 39: 497–505.
  • 70. Corfield EC, Martin NG, Nyholt DR. Familiality and heritability of fatigue in an Australian twin sample. Twin Res Hum Genet 2017; 20: 208–215.
  • 71. Landmark‐Hoyvik H, Reinertsen KV, Loge JH, et al. The genetics and epigenetics of fatigue. PM R 2010; 2: 456–465.
  • 72. Cameron B, Galbraith S, Zhang Y, et al. Gene expression correlates of postinfective fatigue syndrome after infectious mononucleosis. J Infect Dis 2007; 196: 56–66.
  • 73. Galbraith S, Cameron B, Li H, et al. Peripheral blood gene expression in postinfective fatigue syndrome following from three different triggering infections. J Infect Dis 2011; 204: 1632–1640.
  • 74. Schutzer SE, Angel TE, Liu T, et al. Distinct cerebrospinal fluid proteomes differentiate post‐treatment Lyme disease from chronic fatigue syndrome. PLoS One 2011; 6: e17287.
  • 75. Baraniuk JN, Casado B, Maibach H, et al. A chronic fatigue syndrome‐related proteome in human cerebrospinal fluid. BMC Neurol 2005; 5: 22.
  • 76. Ciregia F, Kollipara L, Giusti L, et al. Bottom‐up proteomics suggests an association between differential expression of mitochondrial proteins and chronic fatigue syndrome. Transl Psychiatry 2016; 6: e904.
  • 77. Tomas C, Newton J. Metabolic abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: a mini‐review. Biochem Soc Trans 2018; 46: 547–553.
  • 78. Newberry F, Hsieh SY, Wileman T, Carding SR. Does the microbiome and virome contribute to myalgic encephalomyelitis/chronic fatigue syndrome? Clin Sci (Lond) 2018; 132: 523–542.
  • 79. Castro‐Marrero J, Saez‐Francas N, Santillo D, Alegre J. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome. Br J Pharmacol 2017; 174: 345–369.
  • 80. Collatz A, Johnston SC, Staines DR, Marshall‐Gradisnik SM. A systematic review of drug therapies for chronic fatigue syndrome/myalgic encephalomyelitis. Clin Ther 2016; 38 (1263–1271): e9.
  • 81. Fluge O, Mella O. Clinical impact of B‐cell depletion with the anti‐CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurol 2009; 9: 28.
  • 82. Fluge O, Bruland O, Risa K, et al. Benefit from B‐lymphocyte depletion using the anti‐CD20 antibody rituximab in chronic fatigue syndrome. A double‐blind and placebo‐controlled study. PLoS One 2011; 6: e26358.
  • 83. Fluge O, Rekeland IG, Lien K, et al. B‐lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a randomized, double‐blind, placebo‐controlled trial. Ann Intern Med 2019; 170: 585–593.
  • 84. Sandler CX, Hamilton BA, Horsfield SL, et al. Outcomes and predictors of response from an optimised, multidisciplinary intervention for chronic fatigue states. Intern Med J 2016; 46: 1421–1429.
  • 85. McBride RL, Horsfield S, Sandler CX, et al. Cognitive remediation training improves performance in patients with chronic fatigue syndrome. Psychiatry Res 2017; 257: 400–405.
  • 86. White PD, Goldsmith KA, Johnson AL, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011; 377: 823–836.
  • 87. Sharpe M, Hawton K, Simkin S, et al. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomized controlled trial. BMJ 1996; 312: 22–26.
  • 88. Prins JB, Bleijenberg G, Bazelmans E, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet 2001; 357: 841–847.
  • 89. Price JR, Mitchell E, Tidy E, Hunot V. Cognitive behaviour therapy for chronic fatigue syndrome in adults. Cochrane Database Syst Rev 2008; (3): CD001027.
  • 90. Janse A, Worm‐Smeitink M, Bleijenberg G, et al. Efficacy of web‐based cognitive‐behavioural therapy for chronic fatigue syndrome: randomised controlled trial. Br J Psychiatry 2018; 212: 112–118.
  • 91. Larun L, Brurberg KG, Odgaard‐Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev 2019; (10): CD003200.
  • 92. Larun L, Brurberg KG, Odgaard‐Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev 2017; (4): CD003200.
  • 93. Brimmer DJ, Fridinger F, Lin JM, Reeves WC. US healthcare providers’ knowledge, attitudes, beliefs, and perceptions concerning chronic fatigue syndrome. BMC Fam Pract 2010; 11: 28.
  • 94. Thomas MA, Smith AP. Primary healthcare provision and chronic fatigue syndrome: a survey of patients’ and general practitioners’ beliefs. BMC Fam Pract 2005; 6: 49.
  • 95. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Advisory Committee. Report to NHMRC Chief Executive Officer. Canberra: NHMRC, 2019. https://www.nhmrc.gov.au/about-us/publications/mecfs-advisory-committee-report-nhmrc-chief-executive-officer (viewed Feb 2020).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.